Argos has also developed an interferon - neutralizing antibody for systemic lupus and has developed a CD83 Soluble Protein for Transplant Rejection / Autoimmune Disorders in
late preclinical development.
Not exact matches
Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that new
preclinical data supporting the
development of microbiome therapeutics for immuno - oncology (leveraging gut microbiota to impact tumor immunotherapy) 1 will be presented today by Sceneay et al in the
late breaking poster session at the 2018 American Association for Cancer Research Annual Meeting (AACR) in Chicago.
Supported translational activities will range from very early discovery - based efforts to
late - stage
preclinical development.
One need not look further than the drug in
late - stage
preclinical development at the US National Institute of Neurological Disorders and Stroke (NINDS) in Bethesda, Maryland.